Media Library
icon
-
ImagelockManufacturing / ImageOperators in a clean room
Process operators in a clean room. Manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. -
ImagelockLeadership / ImageMarc Boutin
Novartis has appointed Marc Boutin as Global Head of Patient Engagement & Advocacy. He will join Novartis no later than November 1, 2020. -
ImagelockManufacturing / ImageNovartis Site in Stein, Switzerland
Manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. -
ImagelockManufacturing / ImageOperator with Culture Medium Bag
A process operator with culture medium bag. Manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. -
ImagelockLocations / ImageBad Säckingen Novartis Stein, Switzerland
Manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. -
ImagelockLeadership / ImageSimon Moroney, D.Phil.
Member of the Board of Directors -
ImagelockLeadership / ImageBridgette Heller
Member of the Board of Directors -
ImagelockLeadership / ImageLutz Hegemann, M.D., Ph.D.
President, Global Health & Sustainability -
VideolockManufacturing / VideoManufacturing CAR-T Cell Therapies: The Novartis Approach
Novartis has created a sophisticated process for manufacturing CAR T Cell Therapies. Novartis CAR-T Cell theapy is developed using the patient's own T-Cells which are part of the body immune system and play a central role in fighting disease. -
VideolockScience & Innovation / VideoThe science behind CAR-T cell therapy
An animated overview of the science behind CAR-T cell therapy. -
PDFlockDisease Awareness / Fact SheetChronic myeloid leukemia Background Fact Sheet
Chronic myeloid leukemia, or CML, is a cancer of the blood and bone marrow in which the body overproduces white blood cells. -
PDFlockScience & Innovation / Fact SheetAdvancing Global Health
Our goal is to change the practice of medicine for patients around the world, including previously undeserved populations in developing regions.